Tibolone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Tibolone: From Postmenopausal Osteoporosis to Migraine with Brainstem Aura
One-Sentence Summary
Tibolone is a synthetic steroid originally used for postmenopausal osteoporosis and menopausal symptoms. The TxGNN model predicts it may be effective for migraine with brainstem aura, but there are currently no registered clinical trials and only 2 publications (both indirect, general menopausal migraine literature), so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Postmenopausal osteoporosis (the Singapore licence has no approved indication text on record) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 96.31% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, tibolone is a synthetic steroid whose metabolites have estrogenic, progestogenic and androgenic activity. Its pharmacology data show it acts on estrogen receptor-α (ESR1). Its efficacy in postmenopausal osteoporosis is established, and mechanistically it may be applicable to hormone-related migraine.
Migraine is strongly linked to estrogen fluctuation and withdrawal, particularly around the menopausal transition. A drug that gives steadier, tissue-selective hormonal exposure could plausibly influence attack patterns.
The link remains indirect. The supplied literature addresses menopausal migraine in general and does not address the brainstem aura subtype. Because the original mechanism data are missing, the mechanistic argument rests on general hormone pharmacology rather than direct evidence.
For context, a broader prediction, "migraine disorder" (score 95.79%), has the same supporting literature and is the more sensible research question than the brainstem aura subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16894336 | 2006 | Clinical study (randomised, prospective per abstract; design not fully confirmed) | Menopause | Compared tibolone with low-dose estrogen-progestogen therapy on the course of primary headaches in postmenopausal women requesting hormone therapy; the title indicates the two treatments had different effects |
| 29521155 | 2018 | Review | Climacteric | Hormonal fluctuation, especially during the perimenopause, is an important migraine trigger; different migraine types, with and without aura, are influenced differently |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05423P | LIVIAL TABLET 2.5 mg (N V Organon) | Tablet | Not recorded |
Safety Considerations
- Drug Interactions: The only pharmacology entry on record is its action on estrogen receptor-α (ESR1). No drug-drug interaction data are available.
- Other notes: Tibolone has been associated with rare instances of acute, clinically apparent liver injury. Migraine with aura and stroke-risk considerations in hormone therapy have not been addressed by the data compiled for this report, and tibolone is contraindicated in pregnancy and lactation.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the evidence is only indirect reviews and one small clinical study on general headaches in postmenopausal women. Nothing is specific to migraine with brainstem aura, and package insert safety data are missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Detailed mechanism of action data (MOA)
- Review of the tibolone-versus-low-dose-EPT headache study for migraine-specific outcomes
- Assessment of stroke and thrombosis risk in migraine with aura
- Consideration of the broader "migraine disorder" indication as the primary research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.